Journal of Nuclear Medicine · 2019 · 17 citations · 24 references
MedicineNuclear MedicineOncologyMetastasisMolecular ImagingTumor ProgressionCancer BiomarkersCancer MetabolismCirculating Tumor CellsCirculating Tumor Dna AnalysisColorectal CancerTumor ImagingCirculating Cell-free Dna AnalysisCirculating Tumor BiomarkersCirculating Tumor MarkersColorectal Cancer PrognosisMetabolic Tumor VolumeOutcome PredictionTumor Volume EstimationTumor Volume Measurement
Baseline whole-body metabolically active tumor volume (WB-MATV) measured by <sup>18</sup>F-FDG PET/CT and circulating cell-free DNA (cfDNA) have been separately validated as predictors of overall and progression-free survival (OS/PFS) in chemorefractory metastatic colorectal cancer (mCRC) patients. This study assessed the correlation between WB-MATV and cfDNA, evaluating the added prognostic value of these in combination, along with clinical parameters. <b>Methods:</b> Of 141 mCRC patients included in a prospective multicenter trial, 132 were evaluable for OS/PFS. cfDNA was extracted from 3 mL of plasma and quantified using a fluorometer. All target lesions were delineated on <sup>18</sup>F-FDG PET/CT, and their metabolic volumes were summed to obtain the WB-MATV. <b>Results:</b> Baseline WB-MATV and cfDNA were strongly correlated (<i>r</i> = 0.70; <i>P</i> < 0.001) but showed discordance in 23 of 132 (17%) patients. A multivariate analysis identified 3 independent negative predictors of PFS (high cfDNA, short time since diagnosis, and body mass index < 30) and 5 of OS (high cfDNA, high WB-MATV, body mass index < 30, poor performance status, and short time since diagnosis). Combining WB-MATV and cfDNA increased the overall prognostic value and allowed identification of a subgroup of patients with low cfDNA and high WB-MATV who were associated with intermediate survival (median OS of 8.1 for low-cfDNA/high-MATV patients vs. 12.7 mo for low-cfDNA/low-MATV patients; hazard ratio, 2.04; <i>P</i> = 0.02). <b>Conclusion:</b> This study confirms the added prognostic value of combined circulating cfDNA and PET-based WB-MATV in chemorefractory mCRC patients. The combination of these two biomarkers should provide a firm basis for risk stratification, both in clinical practice and in research trials.
24
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah‐Jane Dawson, Dana W.Y. Tsui, Muhammed Murtaza et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
C.-H. Köhne, David Cunningham, Francesco Di Costanzo et al. · Annals of Oncology · 2002 · 458 citations · Full text
Medicine, Biostatistics, Oncology +12
Josep Tabernero, Heinz‐Josef Lenz, Salvatore Siena et al. · The Lancet Oncology · 2015 · 326 citations · Full text